ATR vs BBIO
AptarGroup vs BridgeBio Pharma, Inc. — AI-powered side-by-side comparison
VS
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
| Metric | ATR | BBIO |
|---|
| AI Score |
69
|
65
|
| Price |
$134.62
|
$83.71
|
| P/E Ratio |
24.06×
|
-23.38×
|
| ROE |
14.7%
|
35.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
28.3%
|
93.1%
|
| Debt / Equity |
0.54×
|
-0.99×
|
| Dividend Yield |
1.4%
|
0.0%
|
| RSI (14) |
48.2
|
56.9
|
| Beta |
0.382
|
0.983
|
| Expected Upside |
+1.6%
|
—
|
AI Committee View
Current Innellis committee reasoning for ATR versus BBIO.
ATR leads by 4 points.
ATR scores 69/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
ATR Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical